Phase II study of elliptinium acetate salvage treatment of advanced breast cancer
- 31 December 1993
- journal article
- clinical trial
- Published by Elsevier BV in European Journal of Cancer
- Vol. 29 (6), 856-859
- https://doi.org/10.1016/s0959-8049(05)80424-1
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Elliptinium Acetate in Metastatic Breast Cancer – a Phase II StudyOncology, 1990
- Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passageBiochemistry, 1985
- Drug-induced antibodies during 2-N-methyl-9-hydroxyellipticinium acetate (NSC-264137) treatment: schedule dependency and relationship to hemolysis.Journal of Clinical Oncology, 1985
- Ellipticine derivatives interacting with model membranes. Influence of quaternarization of nitrogen-2Biochemical Pharmacology, 1984
- Autoxidation of the antitumor drug 9-hydroxyellipticine and its derivativesJournal of Medicinal Chemistry, 1983
- Protein-associated deoxyribonucleic acid strand breaks produced in mouse leukemia L1210 cells by ellipticine and 2-methyl-9-hydroxyellipticiniumBiochemical Pharmacology, 1982
- Drug Dependent Red Cell Antibodies and Intravascular Haemolysis Occurring in Patients Treated with 9 Hydroxy‐Methyl‐EllipticiniumBritish Journal of Haematology, 1980
- Alkaloids of Ochrosia maculata Jacq. (Ochrosia borbonica Gmel.)Journal of Pharmaceutical Sciences, 1968
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961